Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO).